GranuFlo and NaturaLyte Kidney Dialysis Recall
Injured by Dangerous Medication?
GranuFlo and NaturaLyte are acid concentrates produced by Fresenius Medical
Care. The medications are used in dialysate, which is administered to
patients undergoing kidney dialysis. Unfortunately, GranuFlo and NaturaLyte
can significantly increase the chances of a cardiac event, including a
potentially fatal heart attack.
Evidence indicates that Fresenius Medical Care was aware of the potential
dangers of GranuFlo and NaturaLyte but failed to take action to warn the
majority of dialysis clinics throughout the United States. In March of
2012, the FDA issued a Class I Recall Notice providing warning but many
patients had already suffered life-threatening or fatal complications
by this time.
Those who were harmed by GranuFlo or NaturaLyte or individuals who lost
loved ones due to the dangerous medications may have a legal claim against
Fresenius Medical Care. David C. Rash P.A. is representing injured victims
in GranuFlo and NaturaLyte kidney dialysis recall cases against Fresenius
Medical Care to obtain monetary compensation. Attorney Rash has been named
among the Top 100 Trial Lawyers in the United States and has been recognized
among South Florida’s Top Lawyers for mass tort litigation.
GranuFlo and NaturaLyte Complications
GranuFlo and NaturaLyte convert to bicarbonates in the body, which can
cause an overdose of bicarbonates in many patients. A bicarbonate overdose
can cause metal alkalosis, which is a condition of elevated pH levels.
Complications associated with metal alkalosis include:
- Irregular heart-beat
- Cardiac arrest
- Low blood pressure
- Muscles that twitch or spasm
- Tingling or numbness
- Hypoexmia (low oxygen levels)
- Hypercapnia (high carbon dioxide levels)
- Hypokalemia (low potassium)
Evidence indicates that Fresenius may have been aware of the dangers of
GranuFlo and NaturaLyte as far back as 2003 at the time when the drugs
were approved. By November of 2011, it was clear that Fresenius knew of
these complications since more than 900 patients had experienced cardiac
events in the company’s own dialysis clinics.
Fresenius warned of the risks in an internal memorandum sent to the company’s
1,800 dialysis clinics in the U.S., which treated more than 138,000 patients.
Unfortunately, as many as 125,000 patients who were treated at independent
clinics did not receive a warning. Therefore, these dialysis patients
continued to be exposed to dangerous medications long after the dangers
David C. Rash P.A. Can Help Injured Dialysis Victims
Under the law, when a drug manufacturer releases a product, the public
must be warned of any dangers, and the manufacturer must ensure that the
medication is safe prior to distribution. In this case, Fresenius failed
to live up to its legal obligations. Injured victims who suffered complications
due to GranuFlo and NaturaLyte may pursue a claim for damages and those
who lost loved ones may pursue a wrongful death case.
David C. Rash P.A. can help those who have been harmed to seek compensation
through a class action, multi-district litigation or other claim against
Fresenius Medical Care.
Contact us today to set up your free consultation and learn how we can help.